This site is still under development. Information, features, and some organizational
aspects of the data still need further work and will change as we continue building.

HDAC Inhibitor SNDX-275

Hover over a term you want explained. If you need more details, then click on the term and a new tab will open with a full details page.

What HDAC Inhibitor SNDX-275 Means in Everyday Medical Language

HDAC Inhibitor SNDX-275 is another name for the drug entinostat. It belongs to a group of medicines called histone deacetylase (HDAC) inhibitors. These drugs work by blocking enzymes called histone deacetylases, which cancer cells use to grow and divide. By blocking these enzymes, entinostat may help slow down or stop the growth of cancer cells.

Why This Drug Can Matter in Cancer Care

Cancer cells often grow uncontrollably because of changes in how their genes are turned on or off. HDAC inhibitors like entinostat affect gene activity by changing how DNA is packaged inside cells. This can help stop cancer cells from multiplying or cause them to die. Entinostat is being studied in clinical trials to see if it can be an effective treatment for various types of cancer. While it is not yet a standard treatment, researchers hope it may offer new options in the future.

What Patients Might See or Hear About Entinostat

You might come across the names HDAC Inhibitor SNDX-275, entinostat, or SNDX-275 in medical reports, treatment discussions, or clinical trial information. These all refer to the same drug. It’s important to understand that seeing this name does not automatically mean it is part of your treatment plan or diagnosis. Always ask your healthcare team how it applies to your individual care.

Where the Term Might Appear

The term HDAC Inhibitor SNDX-275 or entinostat may appear in your medical records, treatment plans, clinical trial descriptions, or drug information pages. If your care team is considering or using this drug, they will explain what it means for your treatment and what to expect.

What the Term Does Not Automatically Mean

Seeing the name HDAC Inhibitor SNDX-275 or entinostat does not mean you have a specific diagnosis or that this drug is definitely part of your treatment. It also does not guarantee how well the drug will work or what side effects you might have. The term simply refers to a drug being studied for cancer treatment.

Common Confusions and How to Avoid Them

This drug has several names, which can be confusing. It may be called entinostat, HDAC Inhibitor SNDX-275, or just SNDX-275. If you see different names in reports or discussions, ask your care team to clarify. Don’t assume the drug is part of your care without confirmation.

Questions to Ask Your Care Team

If you hear about entinostat or HDAC Inhibitor SNDX-275, consider asking your healthcare providers what role it might play in your treatment, whether it is part of a clinical trial, what benefits and risks it may have, and how it compares to other options. These questions can help you understand your care better.

How to Read the Term in Context

Always look at the term entinostat or HDAC Inhibitor SNDX-275 within the full context of your medical information. It is a drug under study, not a diagnosis or guaranteed treatment. Your healthcare team can explain what it means for you personally.

Safety and Next Steps

This information is for education only and does not decide what treatments are safe or appropriate for you. If you see this term in your records or discussions, the best next step is to ask your care team for personalized information and guidance based on your health and treatment goals.

Sources

Public source information used for this glossary entry includes: